Skip to main content

Priorities

Image result for priority

Most talk of "priorities" is nonsense.

Whenever someone chooses to work on, advocate, or contribute money to A, there will it seems always be someone who says, "but what about B?"

Since there are always a variety of good causes, there will always be a host of possible Bs.

If you contributed to A, then A must be your priority then, right?

Well, no, not necessarily. You could make that true by definition, but the definition will end up being rigged and arbitrary. By any useful definition, prioritizing A over B means valuing A more than B, and it simply is NOT the case that by acting to advance A today I prove that I value A more than B.

I use the algebraic language precisely because the particular range of applications is so broad.

Ask yourself: if I am feeding my cat at this moment, does it follow I value my cat more than my dog? or my child? No: each of the latter two may be well feed and content, the cat may be unfed for this day and meowing angrily about it. The distinction isn't one of valuing, or of "prioritizing" in any non-question-begging sense. The question is only one of what had to be the immediate object of my activity.

Likewise: if a writer is working on one project rather than another right now, does the A have a higher priority? Well ... no. Not unless that's just a confusing way of saying it has a deadline tomorrow, whereas the other project has a deadline further off!

So be careful about such wording, okay troupers?

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…